Plasma Cytokine Atlas Reveals the Importance of TH2 Polarization and Interferons in Predicting COVID-19 Severity and Survival.
COVID-19
SARS-CoV-2
chemokines
cytokines
survival
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
12
2021
accepted:
21
02
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Although it is now widely accepted that host inflammatory response contributes to COVID-19 immunopathogenesis, the pathways and mechanisms driving disease severity and clinical outcome remain poorly understood. In the effort to identify key soluble mediators that characterize life-threatening COVID-19, we quantified 62 cytokines, chemokines and other factors involved in inflammation and immunity in plasma samples, collected at hospital admission, from 80 hospitalized patients with severe COVID-19 disease who were stratified on the basis of clinical outcome (mechanical ventilation or death by day 28). Our data confirm that age, as well as neutrophilia, lymphocytopenia, procalcitonin, D-dimer and lactate dehydrogenase are strongly associated with the risk of fatal COVID-19. In addition, we found that cytokines related to TH2 regulations (IL-4, IL-13, IL-33), cell metabolism (lep, lep-R) and interferons (IFNα, IFNβ, IFNγ) were also predictive of life-threatening COVID-19.
Identifiants
pubmed: 35386702
doi: 10.3389/fimmu.2022.842150
pmc: PMC8979161
doi:
Substances chimiques
Chemokines
0
Cytokines
0
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
842150Informations de copyright
Copyright © 2022 Gibellini, De Biasi, Meschiari, Gozzi, Paolini, Borella, Mattioli, Lo Tartaro, Fidanza, Neroni, Busani, Girardis, Guaraldi, Mussini, Cozzi-Lepri and Cossarizza.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Immunol. 2021 Dec;51(12):2708-3145
pubmed: 34910301
Nat Commun. 2021 Jul 5;12(1):4117
pubmed: 34226537
Sci Rep. 2020 Oct 29;10(1):18689
pubmed: 33122784
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Eur J Immunol. 2022 Mar;52(3):484-502
pubmed: 34870329
EMBO Mol Med. 2020 Dec 7;12(12):e13001
pubmed: 33078545
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34185704
Sci Immunol. 2021 Mar 10;6(57):
pubmed: 33692097
Nat Rev Immunol. 2021 Jan;21(1):49-64
pubmed: 33214719
Front Immunol. 2021 Apr 26;12:668507
pubmed: 33981314
Respir Med Case Rep. 2020;31:101292
pubmed: 33200067
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Cytometry A. 2020 Apr;97(4):340-343
pubmed: 32187834
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
PLoS One. 2013;8(2):e57121
pubmed: 23468921
Int J Obes Relat Metab Disord. 2003 Dec;27(12):1472-8
pubmed: 14634677
Endocr Rev. 2007 Aug;28(5):492-520
pubmed: 17475924
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Cytometry A. 2020 Jul;97(7):668-673
pubmed: 32275124
Front Cell Infect Microbiol. 2021 Feb 26;11:624483
pubmed: 33718270
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
Nat Rev Immunol. 2004 May;4(5):371-9
pubmed: 15122202
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Nat Commun. 2021 Jul 29;12(1):4677
pubmed: 34326336
Front Immunol. 2021 Jun 18;12:649359
pubmed: 34220807
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Sci Rep. 2021 Apr 13;11(1):8059
pubmed: 33850184
Cells. 2021 Jun 23;10(7):
pubmed: 34201847
Am J Respir Crit Care Med. 2013 Jan 1;187(1):65-77
pubmed: 23144331
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Eur J Immunol. 2020 Sep;50(9):1283-1294
pubmed: 32910469
Front Immunol. 2019 Dec 13;10:2759
pubmed: 31921102
Virus Res. 2020 Nov;289:198171
pubmed: 32979474
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Cell. 2020 Oct 29;183(3):837
pubmed: 33125895
Rev Med Virol. 2021 Jul;31(4):e2199
pubmed: 34260778